‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

Detalles Bibliográficos
Autores principales: Annemans, Lieven, Packard, Chris J, Briggs, Andrew, Ray, Kausik K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047410/
https://www.ncbi.nlm.nih.gov/pubmed/29236976
http://dx.doi.org/10.1093/eurheartj/ehx710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047410/
https://www.ncbi.nlm.nih.gov/pubmed/29236976
http://dx.doi.org/10.1093/eurheartj/ehx710

Ejemplares similares